10 powodów, dla których warto stosować cytykolinę Artykuł przeglądowy


Marcin Kopka
Rafał Sochacki


Cytykolina jest substancją endogenną odgrywającą rolę w metabolizmie komórkowym. Może być pomocna w leczeniu udaru mózgu, chorób Parkinsona i Alzheimera, jaskry, po urazach głowy itd. Bezpieczeństwo stosowania cytykoliny zostało potwierdzone w wielu badaniach.


Jak cytować
Kopka , M., & Sochacki , R. (2022). 10 powodów, dla których warto stosować cytykolinę . Medycyna Faktów , 15(1(54), 64-69. https://doi.org/10.24292/01.MF.0122.9


1. Jasielski P, Piędel F, Piwek M et al. Application of Citicoline in Neurological Disorders: A Systematic Review. Nutrients. 2020; 12(10): 3113.
2. Iulia C, Ruxandra T, Costin L-B et al. Citicoline – A neuroprotector with proven effects on glaucomatous disease. Romanian J Ophthalmol. 2017; 61: 152-8.
3. Herskovits AZ, Guarente LP. SIRT1 in Neurodevelopment and Brain Senescence. Neuron. 2014; 81: 471-83.
4. Secades JJ. Citicoline: Pharmacological and clinical review, 2016 update. Rev De Neurol. 2016; 63: S1-S73.
5. Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S et al. Influence of citicoline on citalopram-induced antidepressant activity in depressive- like symptoms in male mice. Physiol Behav. 2018; 195: 151-7.
6. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res. 2003; 73: 308-15.
7. Gandolfi SA, Marchini G, Caporossi A et al. Cytidine 50-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020; 12: 793.
8. Medline C, Warach S, Pettigrew L. Citicoline Monograph. Altern Med Rev. 2008; 13: 50-7.
9. Mehta A, Mahale R, Buddaraju K et al. Neuroprotective Drugs in Acute Ischemic Stroke: Is It Helpful? J Neurosci Rural Pr. 2019; 10: 576-81.
10. Das SK, Ghosh S, Nath T et. al. The effect of citicoline on stroke: A comparative study from the Eastern part of India. Neurol India. 2015; 63: 697-701.
11. Leon-Jimenez C, Chiquete E, Cantu C et al. Citicoline for acute ischemic stroke in Mexican hospitals: A retrospective postmarketing analysis. Methods Find. Exp Clin Pharm. 2010; 32: 325-30.
12. Álvarez-Sabín J, Santamarina E, Maisterra O et al. Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. Int J Mol Sci. 2016; 17: 390.
13. Iranmanesh F, Vakilian A. Efficiency of Citicoline in Increasing Muscular Strength of Patients with Nontraumatic Cerebral Hemorrhage: A Double- blind Randomized Clinical Trial. J Stroke Cereb Dis. 2008; 17: 153-5.
14. Seifaddini R, Hamze MA, Iranmanesh F et al. The Effects of Citicoline on Cerebrovascular Hemodynamic Status in Ischemic Stroke Patients. J Kerman Univ Med Sci. 2017; 24: 480-6.
15. Secades JJ, Alvarez-Sabín J, Castillo J et. al. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cereb Dis. 2016; 25: 1984-96.
16. Dávalos A, Castillo J, Álvarez-Sabín J et al. Oral citicoline in acute ischemic stroke. Stroke. 2002; 33: 2850-7.
17. Overgaard K, Meden P. Citicoline – the first effective neuroprotectant to be combined with thrombolysis in acute ischemic stroke? J Neurol Sci. 2006; 247(2): 119-20.
18. Dávalos A, Alvarez-Sabín J, Castillo J et al. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo- controlled study (ICTUS trial). Lancet. 2012; 380: 349-57.
19. Mitta M, Goel D, Bansal KK et. al. Edaravone – citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India. 2012; 60: 36-8.
20. Spiers PA, Myers D, Hochanadel GS et al. Citicoline Improves Verbal Memory in Aging. Arch Neurol. 1996; 53: 441-8.
21. McGlade E, Locatelli A, Hardy A et al. Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. J Food Nutr Sci. 2012; 6(3): 769-73.
22. McGlade E, Agoston AM, DiMuzio J et al. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord. 2019; 23(2): 121-34.
23. Gareri P, Cotroneo AM, Castagna A et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013; 8: 131-7.
24. Cohen RA, Browndyke JN, Moser DJ et al. Long-Term Citicoline (Cytidine Diphosphate Choline) Use in Patients with Vascular Dementia: Neuroimaging and Neuropsychological Outcomes. Cereb Dis. 2003; 16: 199-204.
25. Cotroneo AM, Castagna A, Putignano S et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013; 8: 131-7.
26. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005; (2): CD000269. http://doi.org/10.1002/14651858.CD000269.pub3.
27. Caamano J, Gomez MJ, Franco A et al. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol. 1994; 16: 211-8.
28. Alvarez XA, Mouzo R, Pichel V et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999; 21(9): 633-44.
29. Piamonte BLC, Espiritu AI, Anlacan VMM. Effects of Citicoline as an Adjunct Treatment for Alzheimer’s Disease: A Systematic Review. J Alzheimers Dis. 2020; 76(2): 725-32.
30. Castagna A, Cotroneo AM, Ruotolo G et al. The CITIRIVAD Study. Citicoline plus rivastigmine in elderly patients affected with dementia study. Clin Drug Investig. 2016; 36: 1059-65.
31. Gareri P, Castagna A, Cotroneo AM et al. The Citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study. J Alzheimers Dis. 2017; 56: 557-65.
32. Trimmel H, Majdan M, Wodak A et al. Citicoline in Severe Traumatic Brain Injury: Indications for Improved Outcome: A Retrospective Matched Pair Analysis From 14 Austrian Trauma Centers. Wien Klin Wochenschr. 2018; 130: 37-44.
33. Shokouhi G, Haghjoo AG, Sattarnezhad N et al. Effects of Citicoline on Level of Consciousness, SerumLevel of Fetuin-A andMatrix Gla-Protein (MGP) in Trauma Patients with Diffuse Axonal Injury (DAI) and GCS _ 8. Turk. J Trauma Emerg Surg. 2014; 20: 410-6.
34. Zafonte RD, Bagiella E, Ansel BM et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012; 308: 1993-2000.
35. Secades JJ. Citicoline for the Treatment of Head Injury: A Systematic Review and Meta-analysis of Controlled Clinical Trials. J Trauma Treat. 2014; 4: 227.
36. Ruggieri S, Zamponi A, Casacchia M et al. Effetti terapeutici della citicolina (citidin difosfo colina) nella sindrome parkinsoniana. Clinica Terapeutica. 1976; 78(6): 515-25.
37. Agnoli A, Ruggieri S, Denaro A et al. New strategies in the management of Parkinson’s disease:A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology. 1982; 8: 289-96.
38. Eberhardt R, Birbamer G, Gerstenbrand F et al. Citicoline in the treatment of Parkinson’s disease. Clin Ther. 1990; 12: 489-95.
39. Que DS, Jamora RDG. Citicoline as Adjuvant Therapy in Parkinson’s Disease: A Systematic Review. Clin Ther. 2021; 43(1): e19-e31.
40. Parisi V, Coppola G, Centofanti M et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. 2008; 173: 541-54.
41. Ottobelli L, Manni GL, Centofanti M et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica. 2013; 229: 219-26.
42. Gandolfi S, Marchini G, Caporossi A et al. Cytidine 5’-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020; 12(3): 793.
43. Jefferis JM, Connor AJ, Clarke MP. Amblyopia. BMJ. 2015; 351: h5811.
44. Campos EC, Schiavi C, Benedetti P et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol. 1995; 233(5): 307-12.
45. Porciatti V, Schiavi C, Benedetti P et al. Cytidine-50-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res. 1998; 7(2): 141-8.
46. Vagge A, Ferro Desideri L, Traverso CE. An update on pharmacological treatment options for amblyopia. Int Ophthalmol. 2020; 40(12): 3591-7.
47. Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs. 2014; 28: 185-93.
48. Lozano-Fernandez R. Efficacy and safety of oral CDP-choline. Drug Res. 1983; 33: 1073-80.
49. Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Meth Findings Experim Clin Pharmacol. 2009; 31: 171-6.
50. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995; 56: 637-60.
51. Wilson JM, Levey AI, Bergeron C et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol. 1996; 40: 428-39.
52. Wignall ND, Brown ES. Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse. 2014; 40(4): 262-8.
53. Renshaw PF, Daniels S, Lundahl LH et al. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine- dependent subjects: a preliminary report. Psychopharmacology (Berl). 1999; 142: 132-8.
54. Licata SC, Penetar DM, Ravichandran C et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addiction Med. 2011; 5: 57-64.
55. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol. 2007; 27: 498-502.